Lista de obras - Mariusz L Hartman - Dominio Público Uruguay

17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines

artículo científico publicado en 2020

17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes

scientific article published on 01 August 2019

Anti-apoptotic proteins on guard of melanoma cell survival ⬇️

artículo científico publicado el 20 de enero de 2013

BCL-w: apoptotic and non-apoptotic role in health and disease

scientific article published on 21 April 2020

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF<sup>V600E</sup> melanoma cells

artículo científico publicado en 2020

BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma

artículo científico publicado en 2016

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity

scientific article published on 07 January 2020

Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro

artículo científico publicado en 2017

Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype

artículo científico publicado en 2014

Inhibitors of HSP90 in melanoma

scientific article published on 01 February 2020

Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia

artículo científico publicado en 2012

MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment

artículo científico publicado en 2015

MITF in melanoma: mechanisms behind its expression and activity.

artículo científico publicado en 2014

Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells

artículo científico publicado en 2014

Non-Apoptotic Cell Death Signaling Pathways in Melanoma

artículo científico publicado en 2020

Parthenolide complements the cell death-inducing activity of doxorubicin in melanoma cells

artículo científico publicado en 2013

Parthenolide enhances dacarbazine activity against melanoma cells

artículo científico publicado en 2013

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations

artículo científico publicado en 2016

Phenotypic diversity of patient-derived melanoma populations in stem cell medium.

artículo científico publicado en 2015

Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro ⬇️

scientific article published on 27 August 2019

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program

artículo científico publicado en 2019

Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy ⬇️

artículo científico publicado el 1 de octubre de 2012

Pro-survival role of MITF in melanoma

artículo científico publicado en 2014

Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia

artículo científico publicado en 2015

TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAFV600E melanoma cells

scientific article published on 17 October 2019

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells

artículo científico publicado en 2017

Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells

scientific article published on 06 January 2019

[BH3 mimetics as a strategy to complement anticancer therapies]

artículo científico publicado en 2012

Lista de obras de Mariusz L Hartman

17-Aminogeldanamycin Inhibits Constitutive Nuclear Factor-Kappa B (NF-κB) Activity in Patient-Derived Melanoma Cell Lines

17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes

Anti-apoptotic proteins on guard of melanoma cell survival ⬇️

BCL-w: apoptotic and non-apoptotic role in health and disease

BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF<sup>V600E</sup> melanoma cells

BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma

Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity

Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro

Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype

Inhibitors of HSP90 in melanoma

Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia

MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment

MITF in melanoma: mechanisms behind its expression and activity.

Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells

Non-Apoptotic Cell Death Signaling Pathways in Melanoma

Parthenolide complements the cell death-inducing activity of doxorubicin in melanoma cells

Parthenolide enhances dacarbazine activity against melanoma cells

Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations

Phenotypic diversity of patient-derived melanoma populations in stem cell medium.

Physiologically Relevant Oxygen Concentration (6% O2) as an Important Component of the Microenvironment Impacting Melanoma Phenotype and Melanoma Response to Targeted Therapeutics In Vitro ⬇️

Plasticity of Drug-Naïve and Vemurafenib- or Trametinib-Resistant Melanoma Cells in Execution of Differentiation/Pigmentation Program

Pro-apoptotic Activity of BH3-only Proteins and BH3 Mimetics: from Theory to Potential Cancer Therapy ⬇️

Pro-survival role of MITF in melanoma

Relationship between in vitro drug sensitivity and clinical response of patients to treatment in chronic lymphocytic leukemia

TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAFV600E melanoma cells

Vemurafenib and trametinib reduce expression of CTGF and IL-8 in V600EBRAF melanoma cells

Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells

[BH3 mimetics as a strategy to complement anticancer therapies]